Welcome to our dedicated page for Sensus Healthcare SEC filings (Ticker: SRTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sensus Healthcare, Inc. (Nasdaq: SRTS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed medical device manufacturer focused on superficial radiotherapy (SRT and IG-SRT) for skin cancer and keloids, Sensus uses these filings to report material events, financial results and governance changes.
Recent Form 8-K filings describe quarterly financial results, where Sensus discusses revenue, unit shipments of SRT systems, Fair Deal Agreement treatment volumes, and the use of non-GAAP metrics such as Adjusted EBITDA. Other 8-Ks outline board developments, including the appointment of independent directors and related committee assignments, with the company noting compliance with Nasdaq independence standards.
Through its SEC reports, Sensus Healthcare also furnishes earnings press releases that include reconciliations between GAAP and non-GAAP financial measures, along with commentary on reimbursement milestones. For example, the company has highlighted the establishment of dedicated CPT codes by the Centers for Medicare & Medicaid Services for superficial radiotherapy used in non-melanoma skin cancer, which it views as important to its commercial strategy.
On Stock Titan, AI-powered tools can help readers interpret these filings by summarizing complex sections, highlighting key figures and pointing out notable changes from prior periods. Users can quickly identify items related to results of operations, board appointments, and other material events, and use the filings archive to follow how Sensus Healthcare’s financial profile and corporate governance have developed over time.
Sensus Healthcare, Inc. director Eric Sachetta reported buying additional company shares in the open market. On this Form 4, he acquired 2,000 shares of common stock at an average price of $3.81 per share. After this transaction, his directly owned holdings increased to 142,113 common shares.
Sensus Healthcare, Inc. submitted a Form 3 identifying Larry Joseph Biscotti as a director-level reporting person. The insider data show no reported buy, sell, acquisition, or disposition transactions, and the transaction summary indicates neutral net activity with zero shares involved.
Sensus Healthcare reports fourth-quarter and full-year 2025 results, with revenues of $4.9 million for the quarter and $27.5 million for the year, both down sharply from 2024. The decline mainly reflects fewer systems sold and reduced sales to the company’s historically largest customer.
Fourth-quarter gross profit was $1.9 million, or 38.8% of revenues, and the company posted a net loss of $3.2 million, or $0.19 per share. For 2025, gross profit was $11.9 million, or 43.3% of revenue, with a net loss of $7.7 million, or $0.47 per share, compared with net income in 2024.
Management highlighted new dedicated CPT reimbursement codes for treating non-melanoma skin cancer with SRT, a more than 300% per-fraction increase versus the prior delivery code, stronger FDA program utilization, and meaningful international demand. Cash and cash equivalents were $22.1 million as of December 31, 2025, with no debt outstanding.
Sensus Healthcare, Inc. has changed its independent auditor following an acquisition of assets related to Berkowitz Pollack Brant Advisors + CPAs, LLP’s capital markets practice by Carr, Riggs & Ingram, LLC (CRI), effective January 1, 2026. On January 13, 2026, the Audit Committee dismissed Berkowitz Pollack Brant as the company’s independent registered public accounting firm and approved CRI as the new auditor.
Berkowitz Pollack Brant’s audit report on the company’s consolidated financial statements for the year ended December 31, 2024 contained no adverse opinion, no disclaimer of opinion, and was not qualified or modified. The company reports no disagreements with Berkowitz Pollack Brant on accounting, disclosure, or audit matters, and notes a previously disclosed material weakness in information technology general controls that was remediated as of December 31, 2024. The company also states it did not consult with CRI on accounting or audit issues before this appointment.
Sensus Healthcare, Inc. reported that its Board of Directors appointed Larry Biscotti as a Class I director on January 5, 2026, with a term running through the company’s annual meeting in 2028. He will receive the same director compensation as other non-employee board members on a pro-rata annual basis.
The company stated that there are no arrangements or understandings with other persons related to his election and that he has no material interest in any transaction requiring disclosure under SEC rules. The Board determined that Mr. Biscotti qualifies as an independent director under Nasdaq listing standards. The company later issued a press release on January 7, 2026, announcing his election.
Sensus Healthcare reported an insider stock grant to one of its leaders. Director and officer Michael Sardano, who serves as President and General Counsel, acquired 40,000 shares of common stock on 12/12/2025 through a restricted stock award under the Sensus Healthcare, Inc. 2017 Equity Incentive Plan.
The restricted shares will vest in four equal annual installments starting on the first anniversary of the grant date. Following this grant, Sardano directly beneficially owns 158,839 shares of Sensus Healthcare common stock, with an additional 1,000 shares held by his spouse, for which he disclaims beneficial ownership.
Sensus Healthcare, Inc. director and officer Michael Sardano filed an amended insider ownership report. The amendment clarifies that his spouse holds 1,000 shares of Sensus Healthcare common stock, which are reported as indirectly owned through his spouse.
The report states that Sardano disclaims beneficial ownership of these 1,000 shares, even though they are attributable to him for reporting purposes. This amendment corrects an earlier report that had shown no indirect ownership of the company’s common stock.
Sensus Healthcare, Inc. director reports open-market stock purchase. A company director filed a Form 4 disclosing the purchase of 7,000 shares of Sensus Healthcare common stock on 11/21/2025 at a price of $3.93 per share. Following this transaction, the director now beneficially owns 140,113 shares, held directly. The filing was made by a single reporting person in their capacity as a director of Sensus Healthcare.
Sensus Healthcare, Inc. (SRTS) reported an insider share purchase by a director. On 11/13/2025, the reporting person bought 2,500 shares of common stock in an open market transaction coded "P" at a price of $4.50 per share. After this transaction, the director beneficially owns 133,113 shares of Sensus Healthcare common stock, held directly. This filing reflects a change in insider ownership rather than an operating or financial update for the company.
Sensus Healthcare, Inc. (SRTS)130,613 shares of Sensus Healthcare common stock directly, reflecting personal holdings. In addition, the filing reports 2,093 shares of common stock held indirectly through the insider's spouse. The form is filed by a single reporting person and indicates the insider's status as a director of the company, with no derivative securities reported.